US Pharma Marketing
For pharma, biotech, and life sciences commercial teams, marginal gains compound. The 5 items below distill what's working right now across HCP engagement, market access, patient services, and brand operations — drawn from current industry signal and what high-performing teams are quietly doing differently.
1. Wire it into your quarterly business review cadence
Top-quartile teams pair this with a tight measurement framework so the spend can be defended in the next zero-based budgeting cycle.
2. Co-own the metrics with market access from day one
This is one of the few plays where the cost of inaction shows up in headline numbers within two quarters, not five.
3. Pressure-test against your top three competitive scenarios
Commercial leaders treating this as a quarterly habit rather than an annual exercise are pulling away from peers in share of voice and share of script.
4. Build the measurement plan before you build the asset
Done right, this protects the brand from late-cycle access surprises and gives medical affairs a credible seat at the commercial planning table.
5. Pilot in one therapeutic area before scaling enterprise-wide
Pair this with a real-world evidence narrative and the payer conversation gets easier; ignore it and the formulary review gets harder.
Putting It Into Practice
None of the items above are revolutionary on their own. The advantage comes from sequencing, measurement, and the discipline to retire activities that no longer move the business. Start with the two or three items most aligned to your next planning cycle, instrument them properly, and let the data decide what scales.
Related Industry Signal
- A new company rises from the ashes of Purdue Pharma — PharmaVoice
- What’s at stake in Amgen’s showdown with the FDA? — PharmaVoice
- Protein degraders gain speed as Arvinas scores landmark approval — PharmaVoice